| Treatment of sleep apnea with cbd |
2023-7-30 |
2023-9-01 |
|
| Treatment of fragile X syndrome with cannabidiol |
2023-1-10 |
2023-3-22 |
|
| Treatment of fragile x syndrome with cannabidiol |
2022-10-20 |
2023-2-23 |
|
| Treatment of irritability in subjects with autism spectrum disorders with … |
2022-10-20 |
2023-4-27 |
|
| Treatment of 22q11.2 deletion syndrome with cannabidiol |
2022-9-30 |
2023-1-26 |
|
| Treatment of 22q11.2 deletion syndrome with cannabidiol |
2022-9-09 |
2023-1-05 |
|
| Treatment of 22q11.2 deletion syndrome with cannabidiol |
2022-9-09 |
2023-1-05 |
|
| Treatment of Fragile X Syndrome with cannabidiol |
2022-8-24 |
2023-10-10 |
2023-10-10 |
| Treatment of behavioral impairment in developmental and epileptic … |
2022-3-17 |
2022-7-14 |
|
| Treatment of refractory seizures |
2021-12-03 |
2022-6-09 |
|
| Cannabidiol for the treatment of refractory seizures |
2021-12-03 |
2023-10-11 |
|
| Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of … |
2021-11-24 |
2022-6-23 |
|
| Treatment of Fragile X Syndrome with Cannabidiol |
2021-6-28 |
2023-3-07 |
|
| Treatment of autism spectrum disorder with cannabidiol |
2021-5-25 |
2023-4-05 |
|
| Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults |
2020-8-18 |
2021-2-04 |
|
| Methods of treatment of osteoarthritis with transdermal cannabidiol gel |
2020-2-12 |
2020-6-04 |
|
| Use of cannabidiol prodrugs in pharmaceutical compositions |
2018-12-13 |
2020-3-03 |
2020-3-03 |
| Methods and compositions for enhancing the viability of microneedle pores |
2014-9-10 |
2015-7-02 |
|
| Transdermally deliverable opioid prodrugs, abuse-resistant compositions and … |
2012-11-07 |
2013-5-16 |
|
| Optical proximity switch |
2012-7-23 |
2015-3-03 |
2015-3-03 |
| Cannabinoid-Containing Compositions and Methods for Their Use |
2012-4-20 |
2012-8-09 |
|
| Transdermal delivery of cannabinoids |
2011-10-12 |
2012-2-09 |
|
| Abuse deterrent transdermal formulations of opiate agonists and agonist- … |
2011-4-04 |
2013-7-09 |
2013-7-09 |
| Transdermally deliverable opioid prodrugs, abuse-resistant compositions and … |
2011-4-04 |
2019-5-14 |
2019-5-14 |
| Transdermal formulations of cannabidiol comprising a penetration enhancer and … |
2010-4-28 |
2010-11-04 |
|
| Cannabinoid-Containing Compositions and Methods for Their Use |
2009-4-29 |
2012-8-09 |
|
| Abuse deterrent transdermal formulations of opiate agonists and agonist- … |
2009-3-26 |
2009-10-01 |
|
| Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and … |
2008-7-30 |
2009-2-05 |
|
| Enhancing transdermal delivery of opioid antagonists and agonists using codrugs … |
2007-10-18 |
2014-2-18 |
2014-2-18 |
| Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and … |
2007-6-15 |
2008-1-10 |
|
| Transdermal delivery of cannabinoids |
2001-12-21 |
2002-8-15 |
|
| Cannabidiol pour le traitement de crises réfractaires |
2021-12-03 |
2023-10-11 |
|
| Cannabidiol zur behandlung von refraktären anfällen |
2021-12-03 |
2023-10-11 |
|